XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026.

Rhea-AI Summary

XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a live webcast on March 18, 2026 at 8:00 AM ET to discuss results and provide a business update.

According to the company, the webcast will be accessible on the Investors "News & Events" page and a replay will be available for 30 days after the live event.

Argus Mar 12 session

+0.12% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – XOMAO

On Mar 12, the day this news came out, XOMAO closed 0.12% above the previous close.

Data tracked by StockTitan Argus for the Mar 12 session.

Key Figures

Earnings date: March 18, 2026 Webcast time: 8:00 am Eastern Time Webcast replay period: 30 days +5 more

Earnings date

March 18, 2026

Scheduled Q4 and full-year 2025 results release

Webcast time

8:00 am Eastern Time

Earnings webcast on March 18, 2026

Webcast replay period

30 days

Availability of earnings webcast replay

Generation Bio cash consideration

$4.2913 per share

Cash portion of consideration in Generation Bio tender offer

Shares tendered

4,722,533 shares

Generation Bio shares validly tendered (~70%)

Mezagitamab milestones (new)

up to $13.0 million

Potential milestones retained under amended Takeda agreement

Series A dividend

$0.53906 per share

Quarterly dividend for 8.625% Series A preferred

Series B depositary dividend

$0.52344 per depositary share

Quarterly dividend for 8.375% Series B depositary shares

Historical Context

5 past events · Latest: Feb 18

5 events

1. Feb 18

   Investor conferences

   24h Move

   +0.0%

   Announced executive presentations and one-on-one meetings at March investor conferences.

2. Feb 09

   Acquisition closing

   24h Move

   +0.2%

   Completed tender offer and acquisition of Generation Bio with cash plus CVR.

3. Jan 12

   CFO transition

   24h Move

   +0.1%

   Long-tenured CFO stepped down and a new CFO with biotech experience was appointed.

4. Dec 30

   Royalty restructuring

   24h Move

   +0.1%

   Amended Takeda collaboration, trading mezagitamab economics for a basket of assets.

5. Dec 22

   Preferred dividends

   24h Move

   -0.2%

   Declared quarterly cash dividends on Series A and Series B preferred securities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

contingent value right, tender offer, cumulative perpetual preferred stock, depositary share

4 terms

contingent value right financial

"stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right (CVR)."

A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.

tender offer financial

"announced it completed its tender offer and acquisition of Generation Bio, Inc."

A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.

View in glossary

cumulative perpetual preferred stock financial

"8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP)"

A cumulative perpetual preferred stock is a share that acts like a long-lasting hybrid between a bond and a dividend-paying stock: it promises regular fixed payments that, if missed, accumulate and must be paid later before common shareholders get dividends, and it has no set maturity date. Investors care because it can provide steady, higher-priority income similar to interest, but with limited capital upside, sensitivity to interest rates, and the risk that payments can be delayed even though they continue to accrue.

depositary share financial

"$0.52344 per depositary share for depositary shares representing 1/1000 of the 8.375% Series B"

A depositary share is a special type of stock that represents ownership in a company but is traded on the stock market like regular shares. It often makes it easier for people to buy and sell shares of companies from other countries or smaller companies that don’t list directly on big exchanges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update.  

The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event.  

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.  

Investor contact:	Media contact:
Juliane Snowden	Kathy Vincent
XOMA Royalty Corporation	KV Consulting & Management
+1-646-438-9754	kathy@kathyvincent.com
juliane.snowden@xoma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will XOMA (NASDAQ: XOMA) release Q4 and full year 2025 results?

XOMA will release fourth quarter and full year 2025 results on March 18, 2026. According to the company, a webcast discussing the results and a business update will begin at 8:00 AM Eastern Time that same day.

How can investors access XOMA's March 18, 2026 webcast about 2025 results?

Investors can access the live webcast via XOMA's Investors "News & Events" page on its website. According to the company, the webcast link will be posted there and a replay will be available for 30 days after the live event.

What time is XOMA's webcast for the Q4 and full year 2025 results on March 18, 2026?

The webcast is scheduled for 8:00 AM Eastern Time on March 18, 2026. According to the company, management will discuss the financial results and provide a business update during the live presentation and Q&A.

Will XOMA provide a replay of the March 18, 2026 webcast for Q4 and 2025 results?

Yes, XOMA will provide a replay of the March 18, 2026 webcast for 30 days following the live event. According to the company, the replay will be accessible on the Investors "News & Events" page on its website.

Where is XOMA (XOMA) hosting the investor webcast for its 2025 results and business update?

XOMA is hosting the investor webcast on its corporate website under the Investors "News & Events" section. According to the company, the page will include the live link and a replay available for 30 days after the event.